KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Accumulated Expenses (2016 - 2025)

Nektar Therapeutics has reported Other Accumulated Expenses over the past 16 years, most recently at $14.0 million for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $14.0 million for Q4 2025, up 40.93% from a year ago — trailing twelve months through Dec 2025 was $14.0 million (up 40.93% YoY), and the annual figure for FY2025 was $14.0 million, up 40.93%.
  • Other Accumulated Expenses for Q4 2025 was $14.0 million at Nektar Therapeutics, up from $12.1 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for NKTR hit a ceiling of $20.0 million in Q3 2021 and a floor of $6.9 million in Q3 2023.
  • Median Other Accumulated Expenses over the past 5 years was $12.6 million (2022), compared with a mean of $12.8 million.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 54.73% in 2022 and later skyrocketed 157.86% in 2024.
  • Nektar Therapeutics' Other Accumulated Expenses stood at $15.5 million in 2021, then plummeted by 54.73% to $7.0 million in 2022, then skyrocketed by 44.48% to $10.1 million in 2023, then decreased by 1.96% to $9.9 million in 2024, then surged by 40.93% to $14.0 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $14.0 million (Q4 2025), $12.1 million (Q3 2025), and $9.8 million (Q2 2025) per Business Quant data.